B3GNT3 and cervical cancer: Intense expression of B3GNT3 protein was noted in 24.7% (21/85), 41.4% (12/29), 58.9% (33/56), and 52.2% (12/23) of cervical cancer of FIGO stage Ib1, Ib2, IIa1and IIa2, respectively (P < 0.05, χ2 test).